
Ami B Patel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4968886/publications.pdf Version: 2024-02-01



ΔΜΙ Β ΡΛΤΕΙ

#	Article	IF	CITATIONS
1	Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and theÂDevelopment of Next Generation ABL Kinase Inhibitors. Hematology/Oncology Clinics of North America, 2017, 31, 589-612.	2.2	125
2	SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia. Blood Cancer Discovery, 2021, 2, 266-287.	5.0	37
3	JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood, 2019, 134, 2388-2398.	1.4	25
4	Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)â€Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. ChemMedChem, 2016, 11, 850-861.	3.2	23
5	BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia. Experimental Hematology, 2019, 77, 36-40.e2.	0.4	14
6	Lysozyme nephropathy in chronic myelomonocytic leukemia. Clinical Case Reports (discontinued), 2019, 7, 1263-1264.	0.5	10
7	Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations. Blood Advances, 2019, 3, 952-955.	5.2	8
8	Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia, 2020, 34, 2981-2991.	7.2	8
9	A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with Myelofibrosis Refractory or Intolerant to JAK Inhibitors. Blood, 2021, 138, 143-143.	1.4	5
10	Genetic complexity of chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2021, 62, 1031-1045.	1.3	4
11	Paraneoplastic opsoclonus associated with squamous cell carcinoma of the tongue. Clinical Neurology and Neurosurgery, 2016, 149, 11-14.	1.4	2
12	Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib. Oncotarget, 2018, 9, 17889-17894.	1.8	1
13	Combining Dasatinib and AC220 Reduces Stroma-Based pSTAT5Y694 in FLT3-ITD+ AML and Overcomes FLT3 TKI Resistance. Blood, 2018, 132, 2641-2641.	1.4	0